Latest by Polly Clayden
Birth Weight and Preterm Delivery Outcomes of Vertically vs Non-Vertically Infected HIV-Positive Pregnant Women
Uninfected infants born to vertically infected HIV-positive women might be at greater risk for lower birth weight than those born to non-vertically infected women, according to findings from the largest cohort of pregnant women to date.
Tenofovir-Containing ART Reduces Bone Mineral Density in Breast-Feeding Women: Results From IMPAACT P1084s
Tenofovir DF-containing ART decreases bone mineral density in HIV-positive, breast-feeding women, according to findings presented at the 8th International Workshop on HIV Paediatrics.
Daily raltegravir was well tolerated and met pharmacokinetic targets in full term HIV-exposed infants at high risk of infection, in a study presented at the 8th International Workshop on HIV Paediatrics.
Brazil will begin to use dolutegravir in its national program early next year. The Ministry of Health has negotiated a 70% price reduction with ViiV Healthcare.
Aurobindo Pharma has received U.S. FDA tentative approval for dolutegravir -- the first generic version to be approved, expected to be launched in sub-Saharan Africa in late 2016.
Simulated exposure following 400 mg efavirenz once daily during third trimester of pregnancy, indicates that the lower dose might be adequate in this population, according to data presented at the 17th International Workshop on Clinical Pharmacology ...
There is broad support for universal treatment of people with HIV among fast track countries, and many are committed to adopting "Treat All" policies by the end of this year, say researchers from the World Health Organisation (WHO). But challenges to...
Dolutegravir-based ART was superior to a boosted atazanavir-based regimen in treatment naive women at 48 weeks, according to data from the ARIA study presented at AIDS 2016.
PROMISE Results Support WHO Recommendations for Pregnant and Breastfeeding Women: More Needs to Be Done to Improve ART Acceptability and Adherence
Continued antiretroviral treatment was safe in women with higher CD4 counts after delivery and associated with improved maternal health -- but virologic failure rates were high -- according to data from the PROMISE study, presented at AIDS2016.
No Increased Resistance With Once-Daily Dosing of Abacavir and 3TC Than Twice-Daily Dosing in the ARROW Trial
Once-daily dosing of abacavir (ABC) and lamivudine (3TC) was non-inferior to twice-daily dosing in development of viral resistance in the ARROW trial, according to data presented at the 8th International Workshop on HIV Pediatrics.